V.R. Archer

488 total citations
14 papers, 354 citations indexed

About

V.R. Archer is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, V.R. Archer has authored 14 papers receiving a total of 354 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 10 papers in Oncology and 2 papers in Surgery. Recurrent topics in V.R. Archer's work include Lung Cancer Treatments and Mutations (10 papers), Lung Cancer Diagnosis and Treatment (5 papers) and Cancer Treatment and Pharmacology (4 papers). V.R. Archer is often cited by papers focused on Lung Cancer Treatments and Mutations (10 papers), Lung Cancer Diagnosis and Treatment (5 papers) and Cancer Treatment and Pharmacology (4 papers). V.R. Archer collaborates with scholars based in United Kingdom, Switzerland and South Korea. V.R. Archer's co-authors include Martin Reck, Petr Zatloukal, Rodryg Ramlau, Joachim von Pawel, J. Mezger, Natasha B. Leighl, C. Manegold, Vera Gorbounova, Victor J. Hirsch and Lucinda Billingham and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and The Oncologist.

In The Last Decade

V.R. Archer

14 papers receiving 342 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
V.R. Archer United Kingdom 8 274 249 77 55 39 14 354
Arnold Cyjon Israel 8 327 1.2× 296 1.2× 65 0.8× 29 0.5× 24 0.6× 18 435
Ludovic Doucet France 10 185 0.7× 172 0.7× 83 1.1× 37 0.7× 71 1.8× 37 323
Samer Tabchi Lebanon 12 141 0.5× 214 0.9× 66 0.9× 22 0.4× 33 0.8× 24 326
Jeffrey M. Crane United States 7 280 1.0× 153 0.6× 146 1.9× 35 0.6× 91 2.3× 10 357
Alison Norton United Kingdom 9 321 1.2× 305 1.2× 45 0.6× 26 0.5× 39 1.0× 10 420
Ming Lin United States 4 324 1.2× 300 1.2× 122 1.6× 21 0.4× 62 1.6× 4 439
M. Castiglione Switzerland 7 186 0.7× 226 0.9× 37 0.5× 86 1.6× 53 1.4× 11 359
Gary Zeger United States 12 151 0.6× 156 0.6× 61 0.8× 55 1.0× 48 1.2× 19 315
Rebecca Herbertson United Kingdom 8 78 0.3× 153 0.6× 48 0.6× 33 0.6× 22 0.6× 18 295
C. Le Péchoux France 7 284 1.0× 205 0.8× 34 0.4× 32 0.6× 30 0.8× 34 348

Countries citing papers authored by V.R. Archer

Since Specialization
Citations

This map shows the geographic impact of V.R. Archer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by V.R. Archer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites V.R. Archer more than expected).

Fields of papers citing papers by V.R. Archer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by V.R. Archer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by V.R. Archer. The network helps show where V.R. Archer may publish in the future.

Co-authorship network of co-authors of V.R. Archer

This figure shows the co-authorship network connecting the top 25 collaborators of V.R. Archer. A scholar is included among the top collaborators of V.R. Archer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with V.R. Archer. V.R. Archer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Solomon, Benjamin, Yi‐Long Wu, Rafał Dziadziuszko, et al.. (2024). 1206MO ALINA: Exploratory biomarker analyses in patients (pts) with resected ALK+ non-small cell lung cancer (NSCLC) treated with adjuvant alectinib vs chemotherapy (chemo). Annals of Oncology. 35. S775–S775. 1 indexed citations
2.
Zhou, Caicun, You Lu, Sang‐We Kim, et al.. (2024). Alectinib Versus Crizotinib in Asian Patients With Treatment-Naïve Advanced ALK-Positive NSCLC: Five-Year Update From the Phase 3 ALESIA Study. JTO Clinical and Research Reports. 5(9). 100700–100700. 2 indexed citations
3.
Zhou, Chengcheng, S-W. Kim, Jianhui Zhou, et al.. (2024). 629MO ALESIA 7-year update: Alectinib vs crizotinib in Asian patients (pts) with treatment-naïve advanced ALK+ non-small cell lung cancer (NSCLC). Annals of Oncology. 35. S1634–S1635. 1 indexed citations
4.
Peters, Solange, Tony Mok, Shirish M. Gadgeel, et al.. (2020). Updated overall survival (OS) and safety data from the randomized, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC.. Journal of Clinical Oncology. 38(15_suppl). 9518–9518. 19 indexed citations
5.
Leighl, N. B., Petr Zatloukal, J. Mezger, et al.. (2009). Efficacy and safety of first-line bevacizumab (Bv) and cisplatin/gemcitabine (CG) in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC) in the BO17704 study (AVAiL). Journal of Clinical Oncology. 27(15_suppl). 8050–8050. 15 indexed citations
6.
7.
Archer, V.R., Martin Reck, Alan B. Sandler, et al.. (2008). Risk of symptomatic central nervous system (CNS) progression and secondary hemorrhage in patients with non-squamous non-small cell lung cancer (NSCLC) receiving bevacizumab (BV)-based first-line therapy. Journal of Clinical Oncology. 26(15_suppl). 8114–8114. 13 indexed citations
8.
Reck, Martin, Joachim von Pawel, Petr Zatloukal, et al.. (2007). C1-06: BO17704: a phase III study of first-line cisplatin and gemcitabine with bevacizumab or placebo in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology. 2(8). S360–S361. 6 indexed citations
9.
10.
11.
Poole, Christopher, et al.. (2003). A retrospective evaluation of the feasibility of intrapatient dose escalation as appropriate methodology for dose-ranging studies for combination cytotoxic regimens. Cancer Chemotherapy and Pharmacology. 52(2). 113–118. 7 indexed citations
12.
Darnton, S. Jane, V.R. Archer, Deborah Stocken, et al.. (2003). Preoperative Mitomycin, Ifosfamide, and Cisplatin Followed by Esophagectomy in Squamous Cell Carcinoma of the Esophagus: Pathologic Complete Response Induced by Chemotherapy Leads to Long-Term Survival. Journal of Clinical Oncology. 21(21). 4009–4015. 41 indexed citations
13.
Archer, V.R., Paul Mulholland, Deborah Stocken, S. Jane Darnton, & D. Ferry. (2001). Combined Results from Three Phase II Trials of Neoadjuvant Chemotherapy in Operable Adenocarcinoma of the Oesophagus. Clinical Oncology. 13(3). 164–169. 7 indexed citations
14.
Archer, V.R., Lucinda Billingham, & M.H. Cullen. (1999). Palliative Chemotherapy: No Longer a Contradiction in Terms. The Oncologist. 4(6). 470–477. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Arnold Cyjon Breakdown of academic impact, for papers by Ludovic Doucet Breakdown of academic impact, for papers by Samer Tabchi Breakdown of academic impact, for papers by Jeffrey M. Crane Breakdown of academic impact, for papers by Alison Norton Breakdown of academic impact, for papers by Ming Lin Breakdown of academic impact, for papers by M. Castiglione Breakdown of academic impact, for papers by Gary Zeger Breakdown of academic impact, for papers by Rebecca Herbertson Breakdown of academic impact, for papers by C. Le Péchoux
Rankless by CCL
2026